Drugs / Beriplex P/N
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02047565 | Oct 2013 → May 2014 | hemorrhagic disease | Daiichi Sankyo | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Beriplex P/N | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02047565 ↗ |
| Modality | Protein / enzyme biologic | “4-factor prothrombin complex concentrate” NCT02047565 ↗ |
| Route | Intravenous | “Intravenous administration of 4F-PCC 50, 25, or 10 IU/kg following administration of edoxaban (60 mg) dose-dependently reversed edoxaban's effects on bleeding duration and...” PMID 25403645 ↗ Nov 2014 |